|Description||AM 1235, a synthetic cannabimimetic indole derivative, is a potent and selective agonist for the cannabinoid receptor, with Ki values of 1.5 and 20.4 nM for the CB1 and CB2 receptors, respectively.|
|Solubility||Soluble in DMSO|
|Storage||Store at -20 °C|
|Application||A potent and selective agonist for the cannabinoid receptor|
|Quality Standard||Enterprise standard|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly.|
|Current Developer||SinSa Labs|
Bay 59-3074 is a novel, selective CB1/CB2 receptor partial agonist(Ki values are 48.3 and 45.5 nM at human CB1 and CB2 receptors respectively).
Leelamine, a diterpene molecule, has weak affinity for the human central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. Leelamine is also a PDK(p...
CB-13 is a dual agonist of the CB1 (IC50 = 15 nM) and CB2 (IC50 = 98 nM) receptors, displays antihyperalgesic activity in a rat model of neuropathic pain with n...
BAY 38-7271, also called as KN 38-7271, is a cannabinoid receptor agonist with analgesic and neuroprotective effects. The doses of BAY 38-7271 in animals needed...
CB1-IN-1 is an antagonist of cannabinoid receptor type 1 (CB1R) located in the peripheral nervous system, which may be significant for pain modulation.
Otenabant, also known as CP-945,598, is a drug which acts as a potent and highly selective CB1 antagonist. It was developed by Pfizer for the treatment of obesi...
AM251 block the inhibitory effects of endocannabinoids and synthetic cannabinoid agonists on transmitter release through an action at presynaptic cannabinoid 1 ...
Rimonabant Hydrochloride, used as a tool to investigate CB receptor properties, it is a selective antagonist of cannabinoid CB1 receptor (Ki = 1.98 nM) and inve...
GSK-554418A is a azaindole Cannabinoid receptor type 2 (CB2) agonist. It can be used for the treatment of chronic pain.
Rimonabant is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane.
BML-190 is a selective cannabinoid CB2 receptor inverse agonist with Ki of 435 nM, with 50-fold selectivity over CB1 receptor.
Levonantrado is a synthetic cannabinoid analog of dronabinol developed by Pfizer in the 1980s. Levonantrado is around 30x more potent than THC, and exhibits ant...
AM 1714, a synthetic cannabimimetic indole derivative, is a potent and selective agonist for the cannabinoid receptor.
L-768242, an indole derivative, has been found to be a CB2 receptor agonist and was once studied to exhibit anti-nociceptive and antihyperalgesic activities in ...
AM 1235, a synthetic cannabimimetic indole derivative, is a potent and selective agonist for the cannabinoid receptor, with Ki values of 1.5 and 20.4 nM for the...
MDA 19, a benzohydrazide derivative, has been found to be a CB2 receptor agonist and could be useful in reducting the Attenuates tactile allodynia of rats. IC50...
A-836339 is a synthetic and potent cannabinoid receptor full agonist. It displays a higher affinity for the peripheral CB2 receptor with Ki value of 0.64 nM ove...
AM1248 is an adamantoylindole derivative acts as a moderately potent agonist for both the cannabinoid receptors CB1 and CB2.
Rosonabant is a CB1 receptor antagonist/inverse agonist originated by Esteve. It is an appetite suppressant for the treatment of obesity. But development of the...
Otenabant HCl is a selective and high affinity antagonist of CB1 with Ki value of 0.7 nM.